後発性希少血液疾患治療薬の世界市場:PNH、ITP、PV、MF、MDS

【英語タイトル】Global Acquired Orphan Blood Diseases Therapeutics Market 2015-2019

Technavioが出版した調査資料(IRTNTR5409)・商品コード:IRTNTR5409
・発行会社(調査会社):Technavio
・発行日:2015年3月11日
・ページ数:114
・レポート言語:英語
・レポート形式:pdf
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD3,000 ⇒換算¥339,000見積依頼/購入/質問フォーム
Five UserUSD3,500 ⇒換算¥395,500見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,500 ⇒換算¥508,500見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日~2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
当調査レポートでは、後発性希少血液疾患治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、業界の構造分析、後発性希少血液疾患治療薬の世界市場規模及び予測、市場シェア、地域別分析、購買基準、市場成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。
【レポートの概要】

About Acquired Orphan Blood Diseases Therapeutics
Acquired orphan blood diseases are rare disorders and are characterized by the body’s inability to produce a sufficient amount of RBCs. This is basically because of the improper functioning of bone marrow to produce RBCs in the blood. This leads to a decrease in platelet counts, which can eventually lead to anemia and thrombosis. The acquired orphan blood diseases are developed in the blood after the post fetal life; they are not caused because of genetic reasons. The major orphan blood diseases that contribute to acquired orphan blood diseases are the following: ITP, MDS, MF PNH, and PV.

TechNavio’s analysts forecast the Global Acquired Orphan Blood Diseases Therapeutics market to grow at a CAGR of 12.29 percent over the period 2014-2019.

[Covered in this Report]
This report covers the present scenario and the growth prospects of the Global Acquired Orphan Blood Diseases Therapeutics market for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sale of marketed drugs used in the treatment of PNH, ITP, PV, MF, and MDS.

TechNavio’s report, the Global Acquired Orphan Blood Diseases Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Acquired Orphan Blood Diseases Therapeutics market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

[Key Regions]
• Americas
• APAC
• EMEA

[Key Vendors]
• Alexion Pharmaceuticals
• Amgen
• Celgene
• F. Hoffmann- La Roche
• GlaxoSmithKline
• Incyte

[Other Prominent Vendors]
• Cyclacel Pharmaceuticals
• CTI Biopharma (Cell Therapeutics)
• Eli Lilly
• Gilead Sciences
• Onconova Therapeutics
• MebVax Therapeutics
• Novartis
• Sanofi
• Shire Pharmaceuticals
• S* Bio Pte

[Market Driver]
• Exemption from Pricing Obstacle
• For a full, detailed list, view our report

[Market Challenge]
• Companies Hesitant to Invest in Rare Diseases Therapeutics
• For a full, detailed list, view our report

[Market Trend]
• Benefit from Untapped Market
• For a full, detailed list, view our report

[Key Questions Answered in this Report]
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

【レポートの目次】

01. Executive Summary

02.List of Abbreviations

03.Scope of the Report
03.1 Market Overview
03.2 Product Offerings

04.Product Profiles
04.1 Soliris
04.2 Nplate
04.3 Revlimid
04.4 Vidaza
04.5 Promacta
04.6 Jakafi
04.7 Rituxan

05.Market Research Methodology
05.1 Market Research Process
05.2 Research Methodology

06.Introduction

07.Diseases Overview
07.1 ITP
07.1.1 Understanding the Disease
07.1.2 Epidemiology
07.1.3 Etiology
07.1.4 Pathophysiology
07.1.5 Management of Disease
07.2 MDS
07.2.1 Understanding the Disease
07.2.2 Epidemiology
07.2.3 Etiology
07.2.4 Pathophysiology
07.2.5 Management of Disease
07.3 MF
07.3.1 Understanding the Disease
07.3.2 Epidemiology
07.3.3 Etiology
07.3.4 Pathophysiology
07.3.5 Management of Disease
07.4 PNH
07.4.1 Understanding the Disease
07.4.2 Epidemiology
07.4.3 Etiology
07.4.4 Pathophysiology
07.4.5 Management of Disease
07.5 PV
07.5.1 Understanding the Disease
07.5.2 Epidemiology
07.5.3 Etiology
07.5.4 Pathophysiology
07.5.5 Management of Disease
07.6 Pipeline Analysis
07.7 Emerging Treatment Options

08.Market Landscape
08.1 Market Overview
08.2 Market Size and Forecast
08.3 Five Forces Analysis

09.Market Segmentation by Indication Type
09.1.1 Market Size and Forecast for ITP
09.1.2 Market Size and Forecast for MDS
09.1.3 Market Size and Forecast for MF
09.1.4 Market Size and Forecast for PNH
09.1.5 Market Size and Forecast for PV

10.Geographical Segmentation

11.Buying Criteria

12.Market Growth Drivers

13.Drivers and their Impact

14.Market Challenges

15.Impact of Drivers and Challenges

16.Market Trends

17.Trends and their Impact

18.Vendor Landscape
18.1 Competitive Scenario
18.1.1 Key News
18.1.2 Mergers and Acquisitions
18.2 Market Share Analysis 2014
18.2.1 Competitive Assessment of Top Drugs
18.2.2 Alexion Pharmaceuticals
18.2.3 Amgen
18.2.4 Celgene
18.2.5 F. Hoffmann-La Roche
18.2.6 GlaxoSmithKline
18.2.7 Incyte
Other Prominent Vendors

19.Key Vendor Analysis
19.1 F. Hoffmann-La Roche Ltd.
19.1.1 Key Facts
19.1.2 Business Overview
19.1.3 Business Segmentation
19.1.4 Business Segmentation by Revenue 2012 and 2013
19.1.5 Sales by Geography
19.1.6 Business Strategy
19.1.7 Key Information
19.1.8 SWOT Analysis
19.2 Celgene
19.2.1 Key Facts
19.2.2 Business Overview
19.2.3 Business Strategy
19.2.4 Business Segmentation by Revenue
19.2.5 Sales by Geography
19.2.6 Key Information
19.2.7 SWOT Analysis
19.3 Alexion
19.3.1 Key Facts
19.3.2 Business Overview
19.3.3 Geographical Segmentation by Revenue 2013
19.3.4 Business Strategy
19.3.5 Recent Developments
19.3.6 SWOT Analysis
19.4 Amgen
19.4.1 Key Facts
19.4.2 Business Overview
19.4.3 Business Segmentation by Revenue 2013
19.4.4 Product Portfolio by Revenue 2013
19.4.5 Business Segmentation by Revenue 2012 and 2013
19.4.6 Geographical Segmentation by Revenue 2013
19.4.7 Business Strategy
19.4.8 Recent Developments
19.4.9 SWOT Analysis
19.5 Incyte
19.5.1 Key Facts
19.5.2 Business Overview
19.5.3 Revenue Segmentation by 2013
19.5.4 Revenue Segmentation by 2012 and 2013
19.5.5 Geographical Segmentation
19.5.6 Business Strategy
19.5.7 Recent Developments
19.5.8 SWOT Analysis
19.6 GlaxoSmithKline
19.6.1 Key Facts
19.6.2 Business Overview
19.6.3 Business Segmentation
19.6.4 Business Segmentation by Revenue 2012 and 2013
19.6.5 Sales by Geography
19.6.6 Pipeline Products
19.6.7 Business Strategy
19.6.8 Key Information
19.6.9 SWOT Analysis
19.6.10 Strengths
19.6.11 Weaknesses
19.6.12 Opportunities
19.6.13 Threats

20.Other Reports in this Series

[List of Exhibits]

Exhibit 1: Market Research Methodology
Exhibit 2: Snapshot of ITP
Exhibit 3: Snapshot of MDS
Exhibit 4: Snapshot of MF
Exhibit 5: Snapshot of PNH
Exhibit 6: Snapshot of PV
Exhibit 7: Global Acquired Orphan Blood Diseases Therapeutics Market 2014-2019 (US$ million)
Exhibit 8: Global Acquired Orphan Blood Diseases Therapeutics Market Segmentation by Indication Type
Exhibit 9: Global Acquired Orphan Blood Diseases Therapeutics Market Revenue Comparison by Indication, 2014 and 2019 (US$ million)
Exhibit 10: Global Acquired Orphan Blood Diseases Therapeutics Market Percent Share by Indication, 2014 and 2019
Exhibit 11: Market Size and Forecast for ITP Market 2014-2019 (US$ million)
Exhibit 12: Market Size and Forecast for MDS Market 2014-2019 (US$ million)
Exhibit 13: Market Size and Forecast for MF Market 2014-2019 (US$ million)
Exhibit 14: Market Size and Forecast for PNH Market 2014-2019 (US$ million)
Exhibit 15: Market Size and Forecast for PV Market 2014-2019 (US$ million)
Exhibit 16: Geographical Segmentation of Global Acquired Orphan Blood Diseases Therapeutics Market in 2014
Exhibit 17: Marketing Exclusivity for Orphan Drugs in Some Regions
Exhibit 18: Revenue Comparison of Top Drugs for Acquired Orphan Blood Diseases Therapeutics market in 2013 (US$ million)
Exhibit 19: Revenue Comparison and YoY Growth for Soliris from 2012-2014 (US$ million)
Exhibit 20: Global Market Forecast for Soliris from 2014-2019 (US$ million)
Exhibit 21: Revenue Comparison and YoY Growth for Nplate from 2011-2013 (US$ million)
Exhibit 22: Revenue Comparison and YoY Growth for Revlimid from 2011-2013 (US$ million)
Exhibit 23: Revenue Comparison and YoY Growth for Vidaza from 2011-2013 (US$ million)
Exhibit 24: Revenue Comparison for Rituxan from 2012-2013 (US$ million)
Exhibit 25: Revenue Comparison and YoY Growth for Promacta 2011-2014 (US$ million)
Exhibit 26: Revenue Comparison for Jakafi from 2012-2013 (US$ million)
Exhibit 27: Business Segmentation of F. Hoffmann-La Roche Ltd. 2013
Exhibit 28: F. Hoffmann-La Roche Ltd.: Business Segmentation by Revenue 2012 and 2013
Exhibit 29: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Pharmaceuticals Division)
Exhibit 30: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Diagnostics Division)
Exhibit 31: Celgene: Business Segmentation by Revenue 2011-2013 (US$ million)
Exhibit 32: Celgene: Sales by Geography 2013
Exhibit 33: Alexion: Geographical Segmentation by Revenue 2013
Exhibit 34: Amgen: Business Segmentation by Revenue 2013
Exhibit 35: Amgen: Product Portfolio by Revenue 2013
Exhibit 36: Amgen: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 37: Amgen: Geographical Segmentation by Revenue 2013
Exhibit 38: Incyte Corporation: Revenue Segmentation by 2013 (US$ million)
Exhibit 39: Incyte Corporation: Revenue Segmentation by 2012 and 2013 (US$ million)
Exhibit 40: Incyte Corporation: Geographical Segmentation
Exhibit 41: GlaxoSmithKline: Business Segmentation 2013
Exhibit 42: GlaxoSmithKline: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 43: GlaxoSmithKline: Sales by Geography 2013
Exhibit 44: GlaxoSmithKline: Pipeline Products 2013



【掲載企業】

Alexion Pharmaceuticals, Amgen, Celgene, F. Hoffmann- La Roche, GlaxoSmithKline, Incyte , Cyclacel  Pharmaceuticals, CTI Biopharma (Cell Therapeutics), Eli Lilly, GileadSciences, Onconova Therapeutics, MebVax Therapeutics, Novartis, Sanofi, Shire Pharmaceuticals, S* Bio Pte 

【レポートのキーワード】

後発性希少血液疾患、治療薬、特発性血小板減少性紫斑病(ITP)、骨髄異形成症候群(MDS)、骨髄線維症(MF)、発作性夜間ヘモグロビン尿症(PNH)、真性多血症(PV)、医薬品

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[後発性希少血液疾患治療薬の世界市場:PNH、ITP、PV、MF、MDS] (コード:IRTNTR5409)販売に関する免責事項を必ずご確認ください。
★調査レポート[後発性希少血液疾患治療薬の世界市場:PNH、ITP、PV、MF、MDS]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆